Editas Medicine (EDIT) Net Income towards Common Stockholders (2015 - 2025)
Editas Medicine (EDIT) reported Net Income towards Common Stockholders of -$25.1 million for Q3 2025, up 59.58% year-over-year from -$15.7 million in Q3 2024, and up 51.21% on a QoQ basis from -$51.5 million in Q2 2025.
Editas Medicine (EDIT) has 11 years of Net Income towards Common Stockholders data on file, last reported at -$25.1 million in Q3 2025.
- Quarterly Net Income towards Common Stockholders rose 59.58% year-over-year to -$25.1 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was -$152.3 million (up 35.78% YoY) and the FY2024 annual result came in at -$237.1 million, down 56.38% from the prior year.
- Net Income towards Common Stockholders climbed to -$25.1 million in Q3 2025 per EDIT's latest filing, from -$51.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$18.9 million in Q4 2023 and bottomed at -$75.7 million in Q1 2025.
- The 5-year median for Net Income towards Common Stockholders is -$51.5 million (2025), against an average of -$50.2 million.
- The widest annual swing landed in 2021, when Net Income towards Common Stockholders tumbled 600.08%; it then surged 68.95% in 2023.
- Tracing EDIT's Net Income towards Common Stockholders over 5 years: stood at -$41.4 million in 2021, then plunged by 46.58% to -$60.7 million in 2022, then surged by 68.95% to -$18.9 million in 2023, then plunged by 140.68% to -$45.4 million in 2024, then surged by 44.67% to -$25.1 million in 2025.
- Per Business Quant, the three latest EDIT Net Income towards Common Stockholders figures stand at -$25.1 million (Q3 2025), -$51.5 million (Q2 2025), and -$75.7 million (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -25.12 Mn |
| Jun 30, 2025 | -51.48 Mn |
| Mar 31, 2025 | -75.66 Mn |
| Dec 31, 2024 | -45.39 Mn |
| Sep 30, 2024 | -62.14 Mn |
| Jun 30, 2024 | -67.61 Mn |
| Mar 31, 2024 | -61.96 Mn |
| Dec 31, 2023 | -18.86 Mn |
| Sep 30, 2023 | -45.02 Mn |
| Jun 30, 2023 | -40.28 Mn |
| Mar 31, 2023 | -47.45 Mn |
| Dec 31, 2022 | -60.73 Mn |
| Sep 30, 2022 | -55.73 Mn |
| Jun 30, 2022 | -53.69 Mn |
| Mar 31, 2022 | -50.28 Mn |
| Dec 31, 2021 | -41.44 Mn |
| Sep 30, 2021 | -39.10 Mn |
| Jun 30, 2021 | -55.26 Mn |
| Mar 31, 2021 | -56.75 Mn |
| Dec 31, 2020 | -62.50 Mn |
| Sep 30, 2020 | 7.82 Mn |
| Jun 30, 2020 | -23.57 Mn |
| Mar 31, 2020 | -37.72 Mn |
| Dec 31, 2019 | -37.77 Mn |
| Sep 30, 2019 | -32.94 Mn |
| Jun 30, 2019 | -33.79 Mn |
| Mar 31, 2019 | -29.25 Mn |
| Dec 31, 2018 | -25.05 Mn |
| Sep 30, 2018 | -15.24 Mn |
| Jun 30, 2018 | -38.72 Mn |
| Mar 31, 2018 | -30.94 Mn |
| Dec 31, 2017 | -36.19 Mn |
| Sep 30, 2017 | -26.60 Mn |
| Jun 30, 2017 | -26.44 Mn |
| Mar 31, 2017 | -31.10 Mn |
| Dec 31, 2016 | -39.38 Mn |
| Sep 30, 2016 | -21.02 Mn |
| Jun 30, 2016 | -19.04 Mn |
| Mar 31, 2016 | -17.79 Mn |
| Dec 31, 2015 | -12.73 Mn |
| Sep 30, 2015 | -7.51 Mn |
| Jun 30, 2015 | -47.67 Mn |
| Mar 31, 2015 | -5.39 Mn |